Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood-Derived Cells

20Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

Abstract

Since the first cord blood transplantation in 1988, umbilical cord blood has become an important option as a source of cells for hematopoietic transplantation. Beyond its role in regenerating the blood and immune systems to treat blood diseases and inherited metabolic disorders, the role of nonhematopoietic progenitor cells in cord blood has led to new and emerging uses of umbilical cord blood in regenerative therapy and immune modulation. In this review, we provide an update on the clinical and preclinical studies using cord blood-derived cells such as mesenchymal stromal cells, endothelial-like progenitor cells, and others. We also provide insight on the use of cord blood cells as vehicles for the delivery of therapeutic agents through gene therapy and microvesicle-associated strategies. Moreover, cord blood can provide essential reagents for regenerative applications. Clinical activity using cord blood cells is increasing rapidly and this review aims to provide an important update on the tremendous potential within this fast-moving field.

Cite

CITATION STYLE

APA

Damien, P., & Allan, D. S. (2015, September 1). Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood-Derived Cells. Biology of Blood and Marrow Transplantation. Elsevier Inc. https://doi.org/10.1016/j.bbmt.2015.05.022

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free